Cited by 81Renal and Vascular PathologiesPeripheral Artery Disease ManagementBlood Pressure and Hypertension Studies

Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: An Updated Systematic Review

Raman, Gowri, Adam, Gaelen P., Halladay, Christopher W., Langberg, Valerie N., Azodo, Ijeoma A., Balk, Ethan M.·2016·Annals of Internal Medicine

Abstract

BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with high blood pressure (BP), decreased kidney function, renal replacement therapy (RRT), and death. PURPOSE: To compare benefits and harms of percutaneous transluminal renal angioplasty with stent placement (PTRAS) versus medical therapy alone in adults with ARAS. DATA SOURCES: MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials from 1993 to 16 March 2016; gray literature; and prior systematic reviews. STUDY SELECTION: Randomized, controlled trials (RCTs); nonrandomized, comparative studies (NRCSs); single-group studies; and selected case reports that reported all-cause and cardiovascular mortality, RRT, kidney function, BP, and adverse events. DATA EXTRACTION: Six researchers extracted data on design, interventions, outcomes, and study quality into a Web-based database. DATA SYNTHESIS: Eighty-three studies met eligibility criteria. In 5 of 7 RCTs, PTRAS and medical therapy led to similar BP control in patients with ARAS, and no RCTs showed statistically significant differences in kidney function, mortality, RRT, cardiovascular events, or pulmonary edema. Eight NRCSs had more variable results, finding mostly no significant differences in mortality, RRT, or cardiovascular events but heterogeneous effects on kidney function and BP. Procedure-related adverse events were rare, and medication-related adverse events were not reported. Two RCTs found no patient characteristics that were associated with outcomes with either PTRAS or medical therapy. Single-group studies found various but inconsistent factors that predict outcomes. Case reports provided examples of clinical improvement after PTRAS in patients with acute decompensation. LIMITATION: Limited clinical applicability and power in RCTs, and possible publication bias and lack of adjusted analyses in NRCSs. CONCLUSION: The strength of evidence regarding the relative benefits and harms of PTRAS versus medical therapy alone for patients with ARAS is low. Studies have generally focused on patients with less severe ARAS. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Integrity signals

Registry

Crossref · 10.7326/m16-1053

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Moderate degrees of renovascular hypertension most often can be managed with medical therapy, particularly with the use of agents that block the renin-angiotensin system (ACE inhibitors/ARBs), as several prospective randomized trials have demonstrated.

    “Moderate degrees of renovascular hypertension most often can be managed with medical therapy, particularly with the use of agents that block the renin-angiotensin system (ACE inhibitors/ARBs), as several prospective randomized trials have demonstrated.309,310”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Raman, G., Adam, G. P., Halladay, C. W., Langberg, V. N., Azodo, I. A., & Balk, E. M.
Affiliations
Tufts Medical Center (US)
Venue
Annals of Internal Medicine
Published
2016-08-16
Volume
165
Issue
9
Pages
635
ISSN
0003-4819 (ISSN-L)
OpenAlex
W2473372812
Cited by
81
References
102
Citations by year
2026: 3 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 13 · 2020: 7 · 2019: 9 · 2018: 6 · 2017: 6
FWCI
6.27
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Agency for Health Care Policy and Research (290-20-1500002 I)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal and Vascular Pathologies
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
atherosclerotic renal artery stenosis, percutaneous transluminal renal angioplasty, renal artery stenting, medical therapy, blood pressure control, renal replacement therapy, renal function, cardiovascular mortality, all-cause mortality, pulmonary edema, acute decompensation, comparative effectiveness
MeSH terms
Adult, Antihypertensive Agents, Humans, Hypertension, Renal Artery Obstruction, Stents, Angioplasty, Renal Insufficiency, Comparative Effectiveness Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review